DekaBank Deutsche Girozentrale Purchases 15,328 Shares of Vertex Pharmaceuticals Incorporated $VRTX

DekaBank Deutsche Girozentrale boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.1% in the second quarter, HoldingsChannel.com reports. The firm owned 506,457 shares of the pharmaceutical company’s stock after acquiring an additional 15,328 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Vertex Pharmaceuticals were worth $223,484,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. United Services Automobile Association bought a new position in Vertex Pharmaceuticals in the first quarter worth about $2,933,000. Lee Johnson Capital Management LLC bought a new position in Vertex Pharmaceuticals in the second quarter worth about $721,000. SteelPeak Wealth LLC bought a new position in Vertex Pharmaceuticals in the second quarter worth about $10,059,000. Moody Lynn & Lieberson LLC grew its stake in shares of Vertex Pharmaceuticals by 1.4% during the second quarter. Moody Lynn & Lieberson LLC now owns 58,077 shares of the pharmaceutical company’s stock worth $25,856,000 after acquiring an additional 822 shares during the last quarter. Finally, New England Research & Management Inc. purchased a new stake in shares of Vertex Pharmaceuticals during the second quarter worth about $472,000. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Trading Up 0.5%

Vertex Pharmaceuticals stock opened at $419.10 on Tuesday. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.88. The stock’s 50 day simple moving average is $396.36 and its two-hundred day simple moving average is $435.71. The firm has a market cap of $107.45 billion, a PE ratio of 29.96 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, topping the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. During the same quarter in the prior year, the firm posted ($12.83) EPS. The business’s quarterly revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Insider Buying and Selling

In related news, Director Bruce I. Sachs acquired 5,000 shares of the stock in a transaction on Wednesday, August 6th. The shares were acquired at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the transaction, the director owned 45,000 shares in the company, valued at approximately $17,535,600. This trade represents a 12.50% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on VRTX. Morgan Stanley dropped their price target on Vertex Pharmaceuticals from $439.00 to $438.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Citigroup boosted their price target on Vertex Pharmaceuticals from $550.00 to $575.00 and gave the stock a “buy” rating in a research note on Thursday, October 2nd. Cantor Fitzgerald dropped their price target on Vertex Pharmaceuticals from $535.00 to $485.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 5th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Wall Street Zen lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 22nd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $494.38.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.